Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Overlooked non-motor Symptoms in Myasthenia Gravis
JNNP 84:989-994, Suzuki, S.,et al, 2013
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice
Neurol 104:e213498, Zara,P.,et al, 2025
A Woman with Subacute Progression of Distal Upper Extremity Weakness
Neurol 105:e214212, Zhao,A.J.,et al, 2025
Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
Ann Neurol 96:1020-1025, Falso,S.,et al, 2024
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis
JAMA Neurol 72:1170-1174, Peeler, C.E.,et al, 2015
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Arch Neurol 66:1334-1338, 1322, Suzuki,S.,et al, 2009
Classification of Myasthenia Gravis Based on Autoantibody Status
Arch Neurol 64:1121-1124, Suzuki,S.,et al, 2007
Mysterious Falls and a Nasal Voice
Lancet 370:712, Bhandari,A. &Adenwalla,F., 2007
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Concomitant Chronic Inflammatory Demyelinating Polyneuropathy and Myasthenia Gravis Following Cytomegalovirus Infection
J Neurol Sci 240:103-106, Mori, M.,et al, 2006
Does This Patient Have Myasthenia Gravis?
JAMA 293:1906-1914, Scherer,K.,et al, 2005
Dysphagia as the Sole Manisfestation of Myasthenia Gravis
JNNP 76:1297-1300, Llabrs,M.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Are MuSK Antibodies the Primary Cause of Myasthenic Symptoms?
Neurol 62:1945-1950,1920, Selcen,D.,et al, 2004
Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis
Arch Neurol 60:243-248, Kupersmith,M.J.,et al, 2003
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathology 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001
Late-Onset Myasthenia Graivs,A Changing Scene
Arch Neurol 56:25-27, Aarli,J.A., 1999
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Myasthenia Gravis During Interferon Alfa Therapy
Neurol 45:382-383, Batocchi,A.P.,et al, 1995
Familial Autoimmune Myasthenia Gravis:Report of Four Families
JNNP 58:729-731, Evoli,A.,et al, 1995
Myasthenia Gravis Complicated by Sarcoidosis
J Thorac Cardiovasc Surg 109:183-184, Takanami,I.,et al, 1995
Familial Autoimmune Myasthenia Gravis
Neurol 44:551-554, Bergoffen,J.,et al, 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Acetylcholine Receptor Antibodies in Juvenile Myasthenia Gravis
Neurol 43:977-982, Andrews,P.I.,et al, 1993
Total Body Irradiation for Myasthenia Gravis:A Long-Term Follow-up
Neurol 43:2215-2221, Durelli,L.,et al, 1993
Seronegative Generalized Myasthenia Gravis:Low Frequency of Thymic Pathology
Neurol 42:586-589, Verma,P.K.&Oger,J-F., 1992
Chronic Limb-Girdle Myasthenia Gravis
Neurol 42:1153-1156, Oh,S.J.&Kuruoglu,R., 1992
Recurrent Transverse Myelitis, Myasthenia Gravis, and Autoantibodies
Ann Neurol 32:407-409, Lindsey,J.W.,et al, 1992
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Neonatal Myasthenia Gravis:A New Clinical & Immunologic Appraisal on 30 Cases
Neurol 38:138-142, Morel,E.,et al, 1988
Genetic Factors in Myasthenia Gravis:A Family Study
Neurol 38:38-42, Kerzin-Storrar,L.,et al, 1988
Seronegative Myasthenia Gravis
Neurol 38:514-517, Soliven,B.C.,et al, 1988
Maternal-Fetal Transmission of Myasthenia Gravis with Acetylcholine-Receptor Antibody
NEJM 318:996, Melber,D., 1988